HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Advances in myeloma treatments, diagnostics have specialists ‘talking about cure’
• Perioperative red blood cell transfusions may increase VTE risk
• Hispanic children with acute lymphoblastic leukemia at higher risk for neurotoxicity
• Autologous HSCT underused despite survival benefits for newly diagnosed multiple myeloma
• Novel laser-sonic scanner shows potential for tumor detection
• Nearly 60% of breast cancer diagnoses delivered by phone
• Palliative care could reduce suicide risk among veterans with advanced lung cancer
• Patient age influences response to immunotherapy for melanoma
• Henry Ford Cancer Institute receives grant to create pancreatic cancer center
• Robotic partial nephrectomy may be superior to open, laparoscopic procedures
• Study to assess immunotherapy combination for HPV-associated head, neck cancers
• Mortality risk after breast cancer greater among those who survived childhood cancers
• Focused ultrasound to open blood-brain barrier could transform glioblastoma treatment delivery
• NCI resource improves research community’s access to clinical trial data, specimens
• Financial advocacy services ‘essential’ for cancer care
• Cisplatin with radiation ‘standard of care’ for HPV-related oral cancers
• Three researchers to be honored at San Antonio Breast Cancer Symposium
• 24-hour cancer clinic reduces ED visits, patient costs
• Addition of chemotherapy to androgen deprivation reduces relapse risk among men with high-risk localized prostate cancer
• Atezolizumab combination extends survival for some patients with metastatic triple-negative breast cancer
• Avelumab-axitinib combination may be new first-line standard for advanced renal cell carcinoma
• Chemoradiation should remain standard for HPV-positive oropharyngeal cancer
• Data analytics, telemedicine aid in cancer survivorship care
• Lenvatinib plus pembrolizumab effective for thyroid cancer subset
• Most breast cancer-related tweets focus on awareness, patient experiences
• Neoadjuvant ipilimumab-nivolumab combination induces major pathological response in mismatch repair-deficient colon cancer
• Nivolumab plus low-dose ipilimumab demonstrates ‘robust’ benefit for certain patients with metastatic colorectal cancer
• One in six premenopausal women with early breast cancer do not adhere to adjuvant tamoxifen
• Pelvic lymph node treatment, short-term ADT improve outcomes in prostate cancer
• Psychosocial therapy reduces fear of disease progression among women with ovarian cancer
• Shorter trastuzumab course cost-effective for early-stage breast cancer
• Emicizumab prophylaxis reduces bleeds associated with hemophilia A without inhibitors
• Patients with low-risk blood clots may be better managed at home
• Minimal residual disease at induction shows value for acute myeloid leukemia
• Duvelisib improves outcomes in leukemia, lymphoma subtypes
• Lenalidomide plus obinutuzumab demonstrates antitumor activity in relapsed follicular B-cell lymphoma
• Childbirth rates among Hodgkin lymphoma survivors match the general population
• Circulating tumor DNA may predict outcomes in aggressive lymphoma
• Fecal transplant may restore gut microbiota after bone marrow transplantation
• Novel tool may better predict myelodysplastic syndrome outcomes
• Inherited breast cancer more common among Nigerian women
• Talazoparib provides significant benefit for germline BRCA-mutated breast cancer
• Resistance to osimertinib for non-small cell lung cancer appears genetically heterogeneous
• Blood test could reduce unnecessary biopsies of lung nodules
• Nivolumab, ipilimumab combination effective for melanoma with brain metastases
• Male BRCA carriers at risk for melanoma, pancreatic cancer
• MUC16 mutation associated with better gastric cancer survival
• Alcohol-related liver cancer has worse prognosis
• Adjuvant radiotherapy improves outcomes for high-risk prostate cancer
• Men with BRAF-mutated papillary thyroid cancer may have worse survival outcomes
• Intensified therapy improves outcomes for childhood B-cell acute lymphoblastic leukemia subgroup
• CAR T-cell therapy appears cost-effective in pediatric leukemia
• Many adult survivors of pediatric CNS tumors do not achieve independence
• Poliovirus shows promise for treatment of advanced glioma
• Immune checkpoint inhibitors linked to myocarditis
• Single-arm trials often miss ‘substantial benefit’ mark
• Insurance rates rise for head, neck cancer among Medicaid expansion states
• HPV testing superior to cytology alone for detecting cervical neoplasia
• Broad-based genomic sequencing fails to improve advanced NSCLC survival
• Supportive therapy alleviates depression associated with advanced cancer
• Study data reveal ‘complexity’ of evaluating benefit of breast cancer screening
• Dose-dense chemotherapy improves bladder cancer outcomes following cystectomy
• Aspirin fails to improve CV outcomes, raises hemorrhage risk in older adults
• Association between extended oral contraceptive use, increased VTE risk may not be clinically significant
• Multicomponent interventions increase colorectal cancer screening rates
• FDA extends LOXO-292 breakthrough therapy designation to RET fusion-positive thyroid cancer
• FDA approves Talzenna for BRCA-mutated, HER2-negative breast cancer
• FDA panel unanimously backs Rituxan biosimilar for lymphoma
• FDA grants Lynparza orphan drug designation for pancreatic cancer
• Imbruvica-Gazyva combination receives priority review for chronic lymphocytic leukemia
• FDA approves Copiktra for leukemia, lymphoma subtypes
• FDA approves Libtayo, first drug specifically for advanced cutaneous squamous cell carcinoma
• FDA grants priority review to selinexor for penta-refractory myeloma
• FDA approves Hemlibra for hemophilia A without factor VIII inhibitors
• FDA authorizes first next-generation sequencing test to detect minimal residual disease in blood cancers
• FDA expands approval of Gardasil 9 for adults aged 27 to 45 years
• FDA approves Tegsedi for polyneuropathy in hereditary transthyretin-mediated amyloidosis
• FDA approves DNA-based assay for blood transfusion compatibility
• FDA: Studies linking cellphone radiation to cancer in rats should not be applied to humans
• Survey: 4 in 10 Americans believe alternative treatments can cure cancer
• Treatment of ‘terribly disabling’ porphyria complicated by disease rarity, misdiagnosis
• Affimed places leukemia, lymphoma trials on hold after patient death
• Phase 3 study of nivolumab for small cell lung cancer fails to meet primary endpoint
• Oncologists, hematologists elected to National Academy of Medicine
• Eight researchers receive ASH bridge grants
• Association of American Cancer Institutes president outlines plan to promote ‘good public policy’
• The Ohio State Comprehensive Cancer Center appoints surgical oncology director
• Cleveland Clinic names urology chair
• Mount Sinai Health System appoints bladder cancer program director